Home / Inspections / 1219707

FDA Inspection 1219707 — Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc. — FEI 1219205

The FDA completed an inspection of Boehringer Ingelheim Pharmaceuticals, Inc. on September 22, 2023 in Ridgefield, CT. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
September 22, 2023
Fiscal Year
2023
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Ridgefield, CT (United States)

Additional Details

Postmarket Adverse Drug Experience (PADE)

Facility

Other inspections at this facility

  • 1281125 (VAI Thu Sep 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1112627 (VAI Thu Dec 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1073537 (VAI Thu Dec 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1004536 (VAI Tue Feb 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 963057 (NAI Fri Feb 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time))

FDA data resources